Ranibizumab

Mosunetuzumab (anti-CD20&CD3e).

Mosunetuzumab (anti-CD20&CD3e).

A potent inhibitor of p38 MAP kinase (IC₅₀ = 35 nM).

InformationPF-06726304 PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively: also inhibits H3K27me3 with the IC50 value of 15 nM.TargetsEzh2 (wild-type) (cell-free): EZH2 Y641N (cell-free)

InformationPF-06726304 PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively: also inhibits H3K27me3 with the IC50 value of 15 nM.TargetsEzh2 (wild-type) (cell-free): EZH2 Y641N (cell-free)

InformationPF-06726304 PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively: also inhibits H3K27me3 with the IC50 value of 15 nM.TargetsEzh2 (wild-type) (cell-free): EZH2 Y641N (cell-free)

InformationPF-06726304 PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively: also inhibits H3K27me3 with the IC50 value of 15 nM.TargetsEzh2 (wild-type) (cell-free): EZH2 Y641N (cell-free)

InformationPF-06726304 PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively: also inhibits H3K27me3 with the IC50 value of 15 nM.TargetsEzh2 (wild-type) (cell-free): EZH2 Y641N (cell-free)

InformationPF-06726304 PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively: also inhibits H3K27me3 with the IC50 value of 15 nM.TargetsEzh2 (wild-type) (cell-free): EZH2 Y641N (cell-free)

InformationPFI-90 PFI-90 is a selective inhibitor of the histone demethylase KDM3B . PFI-90 induces apoptosis and cell differentiation resulting in delayed tumor progression in vivo.

InformationPFI-90 PFI-90 is a selective inhibitor of the histone demethylase KDM3B . PFI-90 induces apoptosis and cell differentiation resulting in delayed tumor progression in vivo.

A cell-permeable thiazolidinedione compound that acts as a potent, ATP-competitive inhibitor against Pim-1/2 kinases (IC 50 = 150 nM and 20 nM against Pim-1 and Pim-2, respectively) as well as DYRK1&#945 (68% inhibition of DYRK1&#945 and Pim-2 at